Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 14, 2025 10:00 ET | Source: Agios Pharmaceuticals, Inc.

Agios to Highlight Pyruvate Kinase Activation Portfolio with New Data in Rare Blood Disorders at 30th EHA Congress

Agios Pharmaceuticals will be featured in oral and poster presentations during the 30th European Hematology Association Congress on June 12-15, 2025.
May 14, 2025 09:30 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress

Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress
February 19, 2025 13:00 ET | Source: DelveInsight Business Research LLP

Oncology Conference Coverage — Stay Ahead in the Oncology Domain with Real-time Coverage from AACR, ESMO, ASCO, ASH, EHA, and Others | DelveInsight

New York, USA, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Oncology Conference Coverage — Stay Ahead in the Oncology Domain with Real-time Coverage from AACR, ESMO, ASCO, ASH, EHA, and Others | DelveInsight ...
June 20, 2024 08:00 ET | Source: Hemex Health

New Research Confirms Hb Variant Test for Sickle Cell, Gazelle™, Useful for Screening and Tracking Treatment Management in Remote Settings, Advancing Doctors’ Abilities to Better Detect and Manage the Disease

PORTLAND, Ore. and ACCRA, Ghana, June 20, 2024 (GLOBE NEWSWIRE) -- Hemex Health announced that the results of two investigations into the effectiveness of their Gazelle™ point-of-care Hb Variant...
June 15, 2024 08:45 ET | Source: Agios Pharmaceuticals, Inc.

Agios Presents Positive Results from Phase 3 ENERGIZE Study of Mitapivat in Non-Transfusion-Dependent Thalassemia in Plenary Session at the European Hematology Association 2024 Hybrid Congress

– ENERGIZE is the First Study to Demonstrate Efficacy of an Oral Treatment for Non-Transfusion-Dependent Alpha- and Beta-Thalassemia – – Additional ENERGIZE Poster Presentation Highlights...
June 14, 2024 07:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting

KT-333 demonstrated initial clinical proof of concept across multiple hematological malignancies, including complete responses in two patients with Hodgkin’s lymphoma Robust STAT3 knockdown and...
June 14, 2024 07:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress

Autolus Therapeutics to Present Three Clinical Data Updates on obe-cel at EHA
June 14, 2024 03:00 ET | Source: Samsung Bioepis

Samsung Bioepis Presents Post-hoc Analysis of Phase 3 Study for EPYSQLI™ (SB12; Eculizumab Biosimilar), at the European Hematology Association (EHA) Congress 2024

Samsung Bioepis Presents Post-hoc Analysis of Phase 3 Study for EPYSQLI™ (SB12; Eculizumab Biosimilar), at the European Hematology Association (EHA) Congre
May 14, 2024 10:00 ET | Source: Kymera Therapeutics, Inc.

Kymera Therapeutics to Present New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting

Abstract released today highlights safety, pharmacodynamic and clinical response data collected through February 6, 2024 cut-off date Updated data to be presented at the European Hematology...
May 14, 2024 10:00 ET | Source: Autolus Therapeutics plc

Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress

Autolus Therapeutics to present three clinical data updates at the 2024 EHA Congress

Next Page keyboard_arrow_right